orlistat

(redirected from Tetrahydrolipstatin)
Also found in: Medical.
Related to Tetrahydrolipstatin: Orlistat

or·li·stat

 (ôr′lĭ-stăt′)
n.
A drug, C29H53NO5, that reduces dietary fat absorption by inhibiting the enzyme lipase, used in the management of obesity.

[or(tho)- + li(p)stat(in), naturally occurring lipase inhibitor (lip(ase) + -stat + -in).]

orlistat

(ˈɔːlɪˌstæt)
n
a drug that promotes weight loss
Translations

orlistat

n orlistat m
References in periodicals archive ?
tetrahydrolipstatin, Orlistat, Alli), also has several known side effects, including unpleasant gastrointestinal issues--steatorrhea (oily, loose stools with excessive intestinal putrefaction and flatus due to unabsorbed fats reaching the large intestine), fecal incontinence, frequent bowel movements and urgency, compromised absorption of fat-soluble vitamins and nutrients, increased appetite and diminished effectiveness over time.
73)) A classical DGL inhibitor, tetrahydrolipstatin (THL), inhibited eCB-STD in some studies, (28)), (75)) (-77)) but not in others.
It is a tetrahydrolipstatin, which is a potent, selective, and reversible inhibitor of gastric and pancreatic lipases.
Tetrahydrolipstatin (Orlistat), a commercial anti-obesity drug, is a known pancreatic lipase inhibitor (Borgstrom, 1988; Hadvary et al.
Tetrahydrolipstatin (THL) was a gift of Hoffmann-La Roche (Basel, Switzerland).
Orlistat (Xenical) contains tetrahydrolipstatin, a nonabsorbed inhibitor of gastric and pancreatic lipase.
More recently, tetrahydrolipstatin (THL; Orlistat[R]) was identified as a nontoxic, active-site inhibitor of mammalian lipases, including LPL (17), which could be used to effectively decrease lipolytic activity in plasma (18).